Research Analysts Offer Predictions for CYCC Q1 Earnings

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) – Stock analysts at Roth Capital issued their Q1 2025 earnings estimates for Cyclacel Pharmaceuticals in a research report issued on Wednesday, November 13th. Roth Capital analyst J. Aschoff forecasts that the biotechnology company will post earnings of ($0.29) per share for the quarter. Roth Capital has a “Hold” rating on the stock. The consensus estimate for Cyclacel Pharmaceuticals’ current full-year earnings is ($2.29) per share. Roth Capital also issued estimates for Cyclacel Pharmaceuticals’ Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.30) EPS.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.36. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%.

Separately, StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals in a research report on Friday. They issued a “sell” rating for the company.

Cyclacel Pharmaceuticals Stock Performance

Shares of Cyclacel Pharmaceuticals stock opened at $0.39 on Thursday. The firm has a 50-day simple moving average of $0.87 and a two-hundred day simple moving average of $1.43. The company has a market cap of $845,595.00, a P/E ratio of -0.04 and a beta of 0.56. Cyclacel Pharmaceuticals has a fifty-two week low of $0.37 and a fifty-two week high of $6.00.

Institutional Trading of Cyclacel Pharmaceuticals

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC bought a new position in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned approximately 9.18% of Cyclacel Pharmaceuticals as of its most recent SEC filing. 23.58% of the stock is currently owned by institutional investors.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.